Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101218 | 0.97 | DGAT1 (0.46) | DGAT1TDP1NFKB1NFKB2RELA | |
| Potassium SCHEMBL29554503 | 0.94 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL6272856 | 0.94 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL6946382 | 0.92 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL3509747 | 0.89 | DGAT1 (0.46) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL17874128 | 0.87 | TDP1 (0.39) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL14949475 | 0.86 | DGAT1 (0.42) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL13401552 | 0.85 | TDP1 (0.38) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL28159512 | 0.85 | TDP1 (0.38) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL3951511 | 0.83 | APLNR (0.41) | DGAT1TDP1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170001981-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2146779-B1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160130250-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2016-05-12 | — | — | US | disclosed |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2003024955-A2 | SMALL MOLECULE INHIBITORS OF CASPASES | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20020128257-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020123487-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | disclosed |
| US-20020040136-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-20020019387-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-02-14 | — | — | US | disclosed |
| WO-2001096346-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
| US-6004823-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5908960-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040136-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | DGAT1 4637/4885TDP1 4723/4885NFKB1 1715/4885 |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20020128257-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | DGAT1 4637/4885TDP1 4723/4885NFKB1 1715/4885 |
| US-20150080368-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20170001981-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20020123487-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | DGAT1 4637/4885TDP1 4723/4885NFKB1 1715/4885 |
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | DGAT1 4637/4885TDP1 4723/4885NFKB1 1715/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20020019387-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | DGAT1 4637/4885TDP1 4723/4885NFKB1 1715/4885 |
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | DGAT1 3219/4885TDP1 4882/4885NFKB1 1141/4885 |
| US-20160130250-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | DGAT1 1690/4885TDP1 4027/4885NFKB1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.